| ABBV |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$3.66 vs. cons $3.60 |
MEDIUM |
| ABBV |
Report |
Global Skyrizi net revenue |
BEAT |
pred ~$5.18B vs. cons $5.05B |
MEDIUM |
| ABBV |
Report |
Worldwide net revenue |
IN-LINE |
pred ~$16.82B vs. cons $16.70B |
MEDIUM |
| ABBV |
Guide |
FY26 adjusted diluted EPS guidance, including disclosed acquired-I PR&D and milestones charges |
BETTER |
guide ~$14.16 vs. cons $14.08 (FY26) |
MEDIUM |
| ABBV |
Guide |
FY26 worldwide net-revenue outlook |
BETTER |
guide ~$67.5B vs. cons $67.4B (FY26) |
LOW |
| ABBV |
Guide |
FY26 Skyrizi revenue outlook |
BETTER |
guide ~$21.8B vs. cons $21.6B (FY26) |
MEDIUM |
| ABBV |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.7% |
— |
MEDIUM |
| ABBV |
Return |
5-day cumulative residual |
+2.8% (FOLLOW-THROUGH) |
A ~$0.06 EPS beat versus $3.60 consensus plus a ~$0.10 FY26 EPS-guide raise versus $14.08 should lift out-period estimates; Skyrizi revenue of ~$5.18B versus $5.05B supports a higher ~$21.8B FY26 outlook versus $21.6B consensus, making the beat more durable than a charge-driven EPS variance. |
MEDIUM |